Loading...
About half of BRCA1-induced breast cancers are negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (so-called “triple-negative breast cancer” [TNBC]). TNBC is a distinct clinical entity that is characterized by younger age and higher grade and stage at diagnosis, higher incidence in blacks, and tendency to involve visceral sites. But does TNBC in BRCA1 mutation carriers differ from TNBC in noncarriers? In a population-based study of 1167 evaluable patients with breast cancer that was diagnosed in patients aged 20 to 49, researchers assessed clinical, pathologic, and lifestyle characteristics in mutation carriers (in whom BRCA1 genes were sequenced) and noncarriers. Of 46 BRCA1 mutation carri…